Allergan
Pfizer in ‘friendly’ merger talks with Allergan
October 29, 2015Sales and Marketing Actavis, Allergan, Pfizer, Teva
Pfizer is in talks with Allergan over what could be the largest takeover deal in an already record-breaking year, it …
Allergan axes 117 jobs in Kythera buyout
October 15, 2015Allergan, Kythera
According to a notice filed with the state of California, Allergan will be laying off 117 employees at Kythera’s Westlake …
Allergan recalls eye drugs after complaints of blurred vision
August 25, 2015Manufacturing and Production Allergan, manufacturing, product recalls, production, recalls
Allergan has issued a recall for batches of eye ointments sold in the US, after customers complained of foreign bodies …
Teva to switch generics focus to Allergan
July 27, 2015Sales and Marketing Allergan, Teva, generics, mergers and acquisitions, pharma mergers and acquisitions
Teva is in negotiations to buy Allergan’s generics division for upwards of $40 billion, according to reports. The generics firm …
Allergan closing manufacturing facility in Iceland
July 14, 2015Manufacturing and Production Actavis, Allergan, Iceland, manufacturing, production, redundancies
Actavis is shutting a plant in Iceland, where its recently-acquired company Actavis has roots, and cutting 300 jobs in the …
Valeant looking to buy Zoetis
June 26, 2015Sales and Marketing Actavis, Allergan, Valeant, Zoetis, brett wells
Canadian drugmaker Valeant Pharmaceuticals has made a move to acquire animal health company Zoetis. This is according to the Wall …
Actavis changes its name to Allergan
June 16, 2015Medical Communications, Sales and Marketing Actavis, Allergan, Botox, Valeant
Actavis has now officially changed its name to Allergan following the Ireland-based company’s recent acquisition of the botox maker. This …
NICE signs-off Roche’s Gazyvaro for leukaemia
June 2, 2015Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia
NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …
Actavis gains new Allergan directors
March 20, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Allergan, Michael Gallagher, Peter McDonnell
Ireland, Dublin-based pharma firm Actavis has added former Allergan members Michael Gallagher and Dr Peter McDonnell to its board of …
Actavis buys generics firm for £306 million
January 26, 2015Manufacturing and Production, Sales and Marketing Actavis, Allergan, Auden McKenzie, generics
Actavis is buying UK-based development and marketing firm Auden McKenzie in a deal worth up to £306 million. The move …
Valeant recalls drug used on hospitalised infants
January 6, 2015Manufacturing and Production, Sales and Marketing Actavis, Allergan, FDA, Valeant, manufacturing, recall, ribavirin, virazole
North American drug firm Valeant Pharmaceuticals has issued a voluntary nationwide recall of Virazole due to microbial contamination. Virazole (ribavirin …
Actavis to axe 200 jobs
December 4, 2014Medical Communications, Sales and Marketing Actavis, Allergan, Forest, GSK, Warner Chilcott, corona, stevenage
Actavis is set to cut 200 jobs in the US just weeks after buying Allergan for $66 billion. The lay-offs …
Actavis buys Allergan for $66 billion
November 18, 2014Medical Communications, Sales and Marketing Actavis, Allergan, Botox, Canada, Valeant, merger
The stately dance between Actavis and Allergan has culminated in the former buying the Botox manufacturer in a $66 billion …
Allergan eyeing Actavis buyout
November 13, 2014Medical Communications, Research and Development, Sales and Marketing Actavis, Allergan, Botox, Valeant, acquisition, buyout, merger
Allergan is attempting to block a recent Valeant hostile takeover bid by seeking the rumoured alternative merger deal with Actavis, …
Allergan and Valeant trade blows as shareholder meeting looms
November 6, 2014Sales and Marketing Actavis, Allergan, Forest, Valeant, merger, warner
Allergan’s efforts to block a key supporter of Valeant’s hostile takeover bid from voting at next month’s special shareholder meeting …
Latest content
FibroFind appoints Lee Borthwick as CEO
